IL17A and pulmonary fibrosis: Because neutralizing IL-17A attenuates bleomycin-induced pulmonary fibrosis by promoting the resolution of inflammatory response [9], we therefore hypothesized that blocking the biological function of IL-17A might have therapeutic benefits against liver fibrosis.